The Claim

In adults with type 2 diabetes and chronic kidney disease, once-weekly subcutaneous semaglutide 1.0 mg reduces the risk of a composite kidney outcome—defined as persistent ≥50% eGFR decline, kidney failure, or death from kidney or cardiovascular causes—by 24% compared to placebo over a median follow-up of 3.4 years, independent of baseline mineralocorticoid receptor antagonist use.

Source: Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
87score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

In adults with type 2 diabetes and kidney disease, a weekly injection of semaglutide at 1.0 mg lowers the combined risk of severe kidney function decline, kidney failure, or death from kidney or heart causes by 24% compared to a placebo over about 3.4 years, regardless of whether they were already taking mineralocorticoid receptor antagonists.

See the scientific wording

In adults with type 2 diabetes and chronic kidney disease, once-weekly subcutaneous semaglutide 1.0 mg reduces the risk of a composite kidney outcome—defined as persistent ≥50% eGFR decline, kidney failure, or death from kidney or cardiovascular causes—by 24% compared to placebo over a median follow-up of 3.4 years, independent of baseline mineralocorticoid receptor antagonist use.

Why this might work

Semaglutide activates receptors in the kidneys that lower blood pressure inside the filtering units, reduce excess sugar and fat in the blood, and decrease the workload on kidney cells, which prevents damage and loss of kidney function over time.

Supported mechanismbased on 1 study

What the research says

1 study
  1. Study: Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis

    This study found that a weekly injection called semaglutide helps protect the kidneys and heart in people with type 2 diabetes and kidney disease, even if they’re already taking another medicine for their kidneys. It lowered their risk of serious kidney or heart problems by about 20–50%, no matter what other meds they were on.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.